We are very grateful to have been part of a fun collaboration with the Kurata lab at the University of Alberta, Edmonton, Calgary on the mechanism of two related potassium channel openers. In two back-to-back manuscripts in JGP we describe how these compounds (one of them in use as an anti-epileptic) require very different drug-channel stoichiometries to affect channel function: despite their resemblance, one of the requires only a single drug binding site per channel tetramer, while the other requires drug binding sites on each of the four channel subunits to have its full effect. Here are the links to the retigabine story and the ICA study.